Platelet-rich plasma (PRP) · Lesson 5 of 25 · 3 min

Types of PRP: leukocyte-rich vs leukocyte-poor and other variations

PRP is a family of preparations, not one product. They differ in white cell content, platelet concentration, source, activation and physical form.

Gloved hands placing a sample tube into a centrifuge

Key takeaways.

  • PRP varies in leukocyte content, platelet concentration, activation status and physical form.
  • Leukocyte-rich PRP includes white blood cells; leukocyte-poor PRP keeps them to a minimum.
  • White blood cells add both antimicrobial factors and pro-inflammatory mediators.
  • More platelets does not simply mean better outcomes; the relationship is complex.
  • Autologous PRP, from the patient's own blood, is the standard approach.
  • PRP can be delivered as a liquid or as a gel with a fibrin scaffold.

Leukocyte-rich and leukocyte-poor PRP

Leukocytes are white blood cells. Leukocyte-rich PRP (L-PRP) is made by collecting the whole buffy coat, so it contains neutrophils, lymphocytes and monocytes along with platelets. Leukocyte-poor PRP (LP-PRP), also called pure PRP, leaves most white cells behind.

The trade-off is real. White cells contribute antimicrobial factors and some growth factors. They also bring pro-inflammatory cytokines and enzymes that break down tissue matrix. The debate over which to use is ongoing, and published trials in the course references reach differing conclusions.

Platelet concentration

It seems intuitive that more platelets would be better. The course material describes the relationship as more complex, with a dose-response pattern and possible biphasic effects. Biphasic means a benefit may level off or reverse beyond a certain point.

Source and activation

Autologous PRP comes from the patient's own blood and is the standard approach. Allogeneic PRP comes from donor blood. It has been explored as an alternative but faces significant practical and regulatory barriers.

Activation status is another variable. Platelets can be activated before injection with an added agent, or left to activate at the treatment site. This choice affects the timing and duration of growth factor release.

Liquid or gel

Liquid PRP is non-activated or minimally activated and stays flowable. It is the form typically used for injection. Gel PRP has a fibrin scaffold, which changes how it is handled and delivered.

These variables interact, so choosing a formulation means weighing the tissue, the patient and the delivery method together. PRP applications are considered off-label.

Educational content for healthcare professionals. Not a treatment recommendation. PRP applications are considered off-label.

Platelet-rich plasma (PRP): 0 of 25 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • A decision framework for choosing a formulation
  • Platelet concentration targets by application
  • Activation agents and techniques
  • When liquid or gel PRP is used
  • Matching leukocyte content to tissue type

Common questions.

What is the difference between leukocyte-rich and leukocyte-poor PRP?
Leukocyte-rich PRP includes white blood cells from the buffy coat. Leukocyte-poor PRP keeps them to a minimum to reduce leukocyte-associated inflammatory factors.
Is a higher platelet count always better in PRP?
Not necessarily. The course material describes a complex dose-response relationship with possible biphasic effects.
Should PRP be activated before injection?
Both approaches are used. Pre-activation and activation at the treatment site differ in the timing and duration of growth factor release, and the choice depends on the application.

Sources

  • Barrachina L, Cequier A, Romero A, et al. Discussing the Debate: Leukocyte-Rich Platelet-Rich Plasma Versus Leukocyte-Poor Platelet-Rich Plasma. Curr Rev Musculoskelet Med. 2024;17(6):243-255. doi:10.1007/s12178-024-09911-0
  • Romandini I, Boffa A, Di Martino A, et al. Leukocytes Do Not Influence the Safety and Efficacy of Platelet-Rich Plasma Injections for the Treatment of Knee Osteoarthritis: A Double-Blind Randomized Controlled Trial. Am J Sports Med. 2024;52(12):3120-3130. doi:10.1177/03635465241283500
  • Le ADK, Enweza L, DeBaun MR, Dragoo JL. The Effect of Platelet Dose on Outcomes after Platelet Rich Plasma Injections for Musculoskeletal Conditions: A Systematic Review and Meta-Analysis. Curr Rev Musculoskelet Med. 2024;17(5):157-167. doi:10.1007/s12178-024-09922-x

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.